<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

XL PI3K/mTOR inhibitor

產(chǎn)品貨號(hào)

Axon 1706 CAS [934529-30-3] MF C31H29N5O6SMW 599.66 Purity: 99% Moderately soluble in DMSO Description Orally active PI3K/mTOR tyrosine kinase inhibitor; matching the profile of XL 765. Note

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

XL PI3K/mTOR inhibitor

Based on 14 reference(s) in Google Scholar 8 10 14

Axon 1706

CAS [934529-30-3]

MF C31H29N5O6S
MW 599.66

Purity: 99%
Moderately soluble in DMSO

XL PI3K/mTOR inhibitor

Description

Orally active PI3K/mTOR tyrosine kinase inhibitor; matching the profile of XL 765.

Note: XL 765 has an updated CAS registry number [934493-76-2].

C Garcia-Echeverria and WR Sellers. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008, 27(41), 5511-5526.

W Gordon et al. Inhibitors of phosphatidylinositol 3-kinases: The next wave of anti-cancer drugs? Chem. New Zealand. 2009, 9-11.

SM Maria, P Furet and F Stauffer. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway. Future Med. Chem. 2009, 1(1), 137-155.

E Vilar et al. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol. Cancer Ther. 2011, 10(3), 395-403.

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & Oncology PI3K mTOR PI3K-Akt-mTOR EC 2.7.11.1

Dual PI3K and mTOR kinase inhibitor

Chemical name

N-(3-(N-(3-(3,5-dimethoxyphenylamino)quinoxalin-2-yl)sulfamoyl)phenyl)-3-methoxy-4-methylbenzamide

Parent CAS No.

[934529-30-3]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>